Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (923)	6/23/1998 9:20:00 PM
From: John Metcalf	Read Replies (1) \| Respond to of 10280

Good point, Andreas. When you survey the devastation in biotech - ARQL down 65% from last Fall, MLNM cut in half, AGPH off a third with the best biotech launch in history -- Sepracor stands out as a company that has gained long-term support. On a technical basis, a significant support level seems to have increased from the mid-thirties to $40, or so. If I had sold at the absolute high, paid taxes, and looked for an opportunity to buy back at advantage, a break-even level still would not have been reached. Currently, we're waiting on levalbuterol approval (nebulizer form), partnering for ICE Prozac, and norastemizole trials. The company has enough cash not to worry about having to raise money in a poor market. Patience is needed more than angst over each day's market action.